DocDollars

Evofem Biosciences, Inc.

CA · United States · Reporting entity ID 100000781819

Total reported 2019–2025
$19.8M
#320 of 2,960 reporting companies — 0% of all reported industry payments
$794K in general payments across 41,930 records, plus $18.2M in research funding across 2,745 records.

How it breaks down

General payments $793,754
Research funding $18,239,952
Ownership & investment $779,977

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Evofem Biosciences, Inc. reported $19.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #320 of 2,960 reporting companies. 92% of that was research funding and 8% general payments such as consulting, speaking, food and travel. 41,930 general payment records and 2,745 research records were filed.

Common questions about Evofem Biosciences, Inc.

How much has Evofem Biosciences, Inc. paid US doctors?

Evofem Biosciences, Inc. reported $19,813,683 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $793,754 in general payments, $18,239,952 in research funding and $779,977 in ownership and investment interests.

How does Evofem Biosciences, Inc. rank among drug and device companies?

It ranks #320 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Evofem Biosciences, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.